Q32 Bio Inc. (0T6G)
LSE
Closed
Aug 25, 2026
Day's Range
16.0152 wk Range
1.62Overview - 0T6G - Q32 Bio Inc.
Key Statistics
Valuation
Enterprise Value
387.13M
Price / Book
‪3.64‬
EV / EBITDA
‪17.74‬
Profitability
Profit Margin
‪62.87%‬
Operating Margin
‪39.93%‬
Return on Assets
‪14.74%‬
Return on Equity
‪72.13%‬
Ownership
Shares Outstanding
37.31M
Float
14.47M
Held by Insiders
‪2.82%‬
Held by Institutions
‪76.26%‬
Price stats
Beta
‪-0.32‬
50-Day Avg
‪0.6630‬
200-Day Avg
‪0.8770‬
Market Cap - 0T6G - Q32 Bio Inc.
Peers - 0T6G - Q32 Bio Inc.
Peer Comparison
Compared with companies in Biotechnology listed on LSE.
- 0T6GLSEQ32 Bio Inc.596.96MMarket Cap+87.72%52-week change—P/E (Trailing)‪62.87%‬Profit Margin
- 0MGBLSEGenmab A/S168.24BMarket Cap+25.25%52-week change30.65P/E (Trailing)‪29.01%‬Profit Margin
- 0QZULSEVertex Pharmaceuticals Incorporated140.31BMarket Cap+29.11%52-week change0.58P/E (Trailing)‪34.99%‬Profit Margin
- 0R2MLSERegeneron Pharmaceuticals, Inc.90.49BMarket Cap+30.71%52-week change0.12P/E (Trailing)‪27.86%‬Profit Margin
- 0A45LSEModerna, Inc.66.31BMarket Cap+81.03%52-week change55.34P/E (Trailing)‪11.32%‬Profit Margin
- 0QW0LSEargenx SE51.17BMarket Cap+30.71%52-week change41.26P/E (Trailing)‪-47.51%‬Profit Margin
- 0NZTLSEUCB SA44.92BMarket Cap+9.88%52-week change127.93P/E (Trailing)‪6.45%‬Profit Margin
Profile Summary - 0T6G - Q32 Bio Inc.
About
Q32 Bio Inc. is a clinical-stage biotechnology company developing biologic therapeutics that target potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Its primary focus is on bempikibart (ADX-914), a fully human anti-IL-7Rα antibody designed to…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
